* Says decision follows independent committee recommendation
* Says to conduct detailed safety and efficacy analysis
* Says decision not to impact 2009 view Oct 2 (Reuters) - SciClone Pharmaceuticals Inc said it discontinued the development of its experimental pancreatic cancer drug following the recommendation by a data safety monitoring committee.
'Further details will be reported when these data have been unblinded and reviewed by SciClone,' the company said in a statement.
The company expects to conduct a detailed safety and efficacy analysis once the data are unblinded. The drug, RP101, was being tested in mid-stage studies to treat late-stage pancreatic cancer. SciClone expects to incur remaining costs related to the mid-stage study during 2009 and does not expect the decision to impact its 2009 forecast adversely.
Shares of the Foster City, California-based company closed at $4.15 Friday on Nasdaq.
(Reporting by Vidya L Nathan in Bangalore; Editing by Maju Samuel) Keywords: SCICLONE/ (vidya.loganathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: vidya.loganathan.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says to conduct detailed safety and efficacy analysis
* Says decision not to impact 2009 view Oct 2 (Reuters) - SciClone Pharmaceuticals Inc said it discontinued the development of its experimental pancreatic cancer drug following the recommendation by a data safety monitoring committee.
'Further details will be reported when these data have been unblinded and reviewed by SciClone,' the company said in a statement.
The company expects to conduct a detailed safety and efficacy analysis once the data are unblinded. The drug, RP101, was being tested in mid-stage studies to treat late-stage pancreatic cancer. SciClone expects to incur remaining costs related to the mid-stage study during 2009 and does not expect the decision to impact its 2009 forecast adversely.
Shares of the Foster City, California-based company closed at $4.15 Friday on Nasdaq.
(Reporting by Vidya L Nathan in Bangalore; Editing by Maju Samuel) Keywords: SCICLONE/ (vidya.loganathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: vidya.loganathan.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2009 AFX News
